The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents. Selective Melanocortin-4 (MC4R) ...
Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. The deal will see Superluminal use its GPCR platform ...
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.
Superluminal and Eli Lilly collaborate to develop small molecule therapeutics targeting GPCRs for cardiometabolic diseases and obesity. Superluminal's AI-driven platform integrates structural biology, ...
Just over a year after launching with $33 million in seed funding, Boston-based Superluminal Medicines is supercharging its small-molecule drug development with a $120 million series A round backed by ...
FUJISAWA, Japan & BOSTON, June 24, 2025--(BUSINESS WIRE)--Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate ...
BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Superluminal Medicines, Inc., “The Membrane Company” using generative biology, chemistry, and machine learning approaches to revolutionize the speed and ...
Eric Solis is founder & CEO of MovoCash, Inc., combining AI, banking & blockchain through MOVO, a highly secure payment card platform. For decades, financial systems have been constrained by the ...
A couple of months ago we reported on an arXiv paper that reported superluminal pulse propagation. The paper was such a steaming pile of science that our report amounted to something along the lines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results